Jan 27 (Reuters) - Ateme SA ATEME.PA :
* FULL YEAR REVENUES UP 15%, 2% LIKE-FOR LIKE
* MONTHLY RECURRING REVENUE UP 30% IN LAST 12 MONTHS;
ENTERING
2022 WITH 23,5MEUR IN ANNUAL RECURING REVENUES
* FY 2022 AND MID-TERM FINANCIAL OBJECTIVES CONFIRMED
* TOTAL REVENUES FOR YEAR TO DECEMBER 31, 2021 STOOD AT
EUR81.1
MILLION, UP 15% VERSUS 2020 AND BY 2% ON A LIKE-FOR-LIKE BASIS.
* ATEME IS STARTING YEAR WITH OVER 23.5 MILLION EUROS IN
RECURRING
REVENUES, STRONGLY IMPROVING QUALITY AND VISIBILITY OF OUR
TOPLINE
* LOOKING AHEAD, INTEGRATION OF ANEVIA IS NOW 100% COMPLETE
WITH
SYNERGIES SET TO MATERIALIZE IN 2022
* PRODUCT MIX IN SECOND HALF BEING SIMILAR THAT OF FIRST
HALF,
GROSS MARGIN IS EXPECTED IN RANGE OF 60% VERSUS 55% IN 2020.
* SALES GROWTH TARGET OF 10% TO 15% AND EBITDA TARGET OF 5
TO 10
MILLION EUROS ARE CONFIRMED FOR PERIOD 2022 - 2023
* IMPROVEMENT CONTINUES TO BE REINVESTED IN THE DEVELOPMENT
OF THE
BUSINESS, NOTABLY THROUGH RESEARCH AND DEVELOPMENT, WITH A
GLOBAL HEAD COUNT (IN TERMS OF FTE) UP FROM 445 TO 486;
CONSEQUENTLY, EBITDA IS EXPECTED AROUND BREAKEVEN
Source text for Eikon: ID:nACT72950
Further company coverage: ATEME.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))